Cargando…

Endocrine immune-related adverse events in patients with metastatic renal and urothelial cancer treated with immune checkpoint-inhibitors

PURPOSE: To evaluate the incidence, diagnosis and treatment of immune-related adverse events (e-irAE) of checkpoint inhibition (ICI) in metastatic urothelial carcinoma (mUC) and metastatic renal cell carcinoma (mRCC). METHODS: A retrospective, single-center study was conducted to identify a cohort t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Oppolzer, Immanuel Augustin, Riester, Josef, Büttner, Roland, Burger, Maximilian, Schnabel, Marco Julius
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Netherlands 2023
Materias:	Urology - Original Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10329606/ https://www.ncbi.nlm.nih.gov/pubmed/37271776 http://dx.doi.org/10.1007/s11255-023-03635-9

Ejemplares similares

Efficacy of Vinflunine for Patients with Metastatic Urothelial Cancer after Immune Checkpoint Inhibitor Pretreatment—A Retrospective Multicenter Analysis
por: Riedel, Felix, et al.
Publicado: (2022)

Metastatic Pleural Effusion: An Unusual Presentation of Urothelial Bladder Carcinoma
por: Javed, Isma N, et al.
Publicado: (2019)

Prognostic Models for Renal Cell Carcinoma in the Era of Immune Checkpoint Therapy
por: Parosanu, Andreea, et al.
Publicado: (2022)

Immune checkpoint inhibitors, endocrine adverse events, and outcomes of melanoma
por: Karhapää, Hanna, et al.
Publicado: (2022)

Temporary Tumor Shrinkage Following Enfortumab Vedotin Therapy for Metastatic Urothelial Carcinoma After Radical Cystectomy With Neoadjuvant Chemotherapy: A Case Report
por: Namiki, Sanae, et al.
Publicado: (2023)

Management of endocrine immune-related adverse events of immune checkpoint inhibitors: an updated review
por: Stelmachowska-Banaś, Maria, et al.
Publicado: (2020)

Clinical Presentation of Immune-Related Endocrine Adverse Events during Immune Checkpoint Inhibitor Treatment
por: Chieng, Jenny Hui Ling, et al.
Publicado: (2022)

Nephroureterectomy of Right-to-Left Crossed Fused Renal Ectopia with Urothelial Carcinoma
por: Hearn, Jason, et al.
Publicado: (2020)

The “One-to-Many” Survival Analysis to Evaluate a New Treatment in Comparison With Therapeutic Alternatives Based on Reconstructed Patient Data: Enfortumab Vedotin Versus Standard of Care in Advanced or Metastatic Urothelial Carcinoma
por: Messori, Andrea, et al.
Publicado: (2022)

Biomarkers of the Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma
por: Chen, Siteng, et al.
Publicado: (2020)

Endocrine‐related adverse events associated with immune‐checkpoint inhibitors in patients with melanoma
por: Kassi, Eva, et al.
Publicado: (2019)

Effect of Arsenate and p-Phenylenediamine on the Expression of Aquaporins in Cultured Human Urothelial Cells
por: Wu, Yi-Hsiao, et al.
Publicado: (2023)

(89)Zirconium-labelled girentuximab ((89)Zr-TLX250) PET in Urothelial Cancer Patients (ZiPUP): protocol for a phase I trial of a novel staging modality for urothelial carcinoma
por: Al-Zubaidi, Mohammed, et al.
Publicado: (2022)

Urothelial Carcinoma of the Bladder With Primary Metastasis to the Brain: A Case Report and Literature Review
por: Sankhyan, Madhav, et al.
Publicado: (2022)

Insights Into the Host Contribution of Endocrine Associated Immune-Related Adverse Events to Immune Checkpoint Inhibition Therapy
por: Chye, Adrian, et al.
Publicado: (2022)

Adverse Effects and Toxicity of Immune Checkpoint Inhibitors For Patients With Urothelial Carcinoma
por: Wang, Di, et al.
Publicado: (2021)

Oncological Outcomes of Non-Urothelial Bladder Cancers in a Specialized Cancer Hospital of a Developing Country
por: Adnan, Siddique, et al.
Publicado: (2020)

Pituitary Metastasis From Urothelial Carcinoma: A Case Report and Review of the Diagnosis and Treatment of Pituitary Metastases
por: Bailey, David, et al.
Publicado: (2021)

Radical Cystectomy and Ileal Conduit Diversion for Bladder Urothelial Carcinoma With Sarcomatoid and Squamous Variants After Renal Transplantation
por: Yavuzsan, Abdullah H, et al.
Publicado: (2020)

FRI539 Vitamin D and Endocrine Immune-Related Adverse Events in Patients Treated with Immune Checkpoint Inhibitors
por: He, Zijun, et al.
Publicado: (2023)

A Primary Urothelial Carcinoma Presenting as a Mid-Bulbar Urethral Stricture in a 30-Year-Old Male
por: Alghafees, Mohammad A, et al.
Publicado: (2021)

Competing-risks nomogram for predicting cancer-specific death in upper tract urothelial carcinoma: a population-based analysis
por: Li, Chengzhuo, et al.
Publicado: (2021)

Diagnostic Ureteroscopy in CT Urography-Diagnosed Upper Tract Urothelial Carcinoma: Delay in Definitive Treatment and Increased Intravesical Recurrence
por: SHSM, Hadi, et al.
Publicado: (2021)

Plasmacytoid Variant Urothelial Cell Carcinoma: A Case of a Histological Variant of Urinary Bladder Cancer With Aggressive Behavior
por: Alshahwan, Mosaad I, et al.
Publicado: (2023)

Immune checkpoint inhibitor therapy for pediatric cancers: A mini review of endocrine adverse events
por: Ihara, Kenji
Publicado: (2019)

Immune checkpoint inhibitors for urothelial carcinoma
por: Kim, Hyung Suk, et al.
Publicado: (2018)

Outlook into the future of front-line immune checkpoint inhibition in metastatic urothelial carcinoma
por: Brown, Jason R., et al.
Publicado: (2021)

Immune Checkpoint Inhibitors and Long-term Survival of Patients With Metastatic Urothelial Cancer
por: Zhu, Alec, et al.
Publicado: (2023)

Conditional immune toxicity rate in patients with metastatic renal and urothelial cancer treated with immune checkpoint inhibitors
por: Nuzzo, Pier Vitale, et al.
Publicado: (2020)

Fournier´s Gangrene Under Sodium-Glucose Cotransporter 2 Inhibitor Therapy as a Life-Threatening Adverse Event: A Case Report and Review of the Literature
por: Rodler, Severin, et al.
Publicado: (2019)

The arguments for an early cystectomy in patients with urothelial carcinoma
por: Barski, Dimitri
Publicado: (2014)

Rarest of the Rare Metastatic Tubulocystic Carcinoma of Kidney
por: Yousuf, Hira, et al.
Publicado: (2020)

Metastatic Prostate Adenocarcinoma: A Rare Presentation
por: Rodriguez, Pierre, et al.
Publicado: (2022)

Efficacy of neoadjuvant atezolizumab treatment in patients with advanced urothelial bladder cancer according to the BASQ classification: a study protocol for an open-label, two-cohort, phase II trial
por: Yuk, Hyeong Dong, et al.
Publicado: (2020)

Endocrine Toxicity and Outcomes in Patients With Metastatic Malignancies Treated With Immune Checkpoint Inhibitors
por: Al Ashi, Suleiman I, et al.
Publicado: (2021)

Combination of pembrolizumab and BCG treatment after endoscopic ablation of high-risk superficial upper urinary tract urothelial carcinoma in patients not candidates for radical nephroureterectomy: protocol for phase-II study
por: Jamil, Marcus L, et al.
Publicado: (2019)

Metastatic Urothelial Carcinoma from Transplanted Kidney with Complete Response to an Immune Checkpoint Inhibitor
por: Chiang, Ryan S., et al.
Publicado: (2020)

Subsequent Systemic Therapy following Platinum and Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma
por: Hong, Joohyun, et al.
Publicado: (2022)

Immune Checkpoint Inhibitors in the Management of Urothelial Carcinoma
por: Patel, Aakash, et al.
Publicado: (2021)

Tumor cell PD-L1 expression is a strong predictor of unfavorable prognosis in immune checkpoint therapy-naive clear cell renal cell cancer
por: Möller, Katharina, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_c1edshe4dih98ka5i1ofd8ktms